JP2022534813A5 - - Google Patents
Info
- Publication number
- JP2022534813A5 JP2022534813A5 JP2022515977A JP2022515977A JP2022534813A5 JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5 JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell population
- grna
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852238P | 2019-05-23 | 2019-05-23 | |
| US62/852,238 | 2019-05-23 | ||
| US202062962127P | 2020-01-16 | 2020-01-16 | |
| US62/962,127 | 2020-01-16 | ||
| PCT/US2020/034391 WO2020237217A1 (en) | 2019-05-23 | 2020-05-22 | Compositions and methods for cd33 modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534813A JP2022534813A (ja) | 2022-08-03 |
| JP2022534813A5 true JP2022534813A5 (cg-RX-API-DMAC7.html) | 2023-05-24 |
Family
ID=71078652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515977A Pending JP2022534813A (ja) | 2019-05-23 | 2020-05-22 | Cd33改変のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220228153A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3973057A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022534813A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035877A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114423865A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020280103A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141732A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020237217A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102709603B1 (ko) * | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US20230407337A1 (en) * | 2020-12-08 | 2023-12-21 | The Regents if the University of California | Crispr ribonucleoprotein complex genome editing of human innate immune cells |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| EP4381062A1 (en) | 2021-08-02 | 2024-06-12 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| EP3129485B2 (en) | 2014-04-09 | 2022-12-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
| WO2017053729A1 (en) * | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| IL258491B2 (en) * | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CN110249052B (zh) | 2016-12-30 | 2024-04-12 | 爱迪塔斯医药公司 | 合成的指导分子、组合物和与其相关的方法 |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| EP3676372A4 (en) * | 2017-08-28 | 2021-06-02 | The Trustees of Columbia University in the City of New York | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33 |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| JP7784707B2 (ja) * | 2019-01-16 | 2025-12-12 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 系統特異的抗原の阻害のための組成物および方法 |
-
2020
- 2020-05-22 AU AU2020280103A patent/AU2020280103A1/en not_active Abandoned
- 2020-05-22 KR KR1020217041969A patent/KR20220035877A/ko not_active Withdrawn
- 2020-05-22 WO PCT/US2020/034391 patent/WO2020237217A1/en not_active Ceased
- 2020-05-22 JP JP2022515977A patent/JP2022534813A/ja active Pending
- 2020-05-22 EP EP20732076.3A patent/EP3973057A1/en not_active Withdrawn
- 2020-05-22 CN CN202080050633.7A patent/CN114423865A/zh active Pending
- 2020-05-22 US US17/613,387 patent/US20220228153A1/en not_active Abandoned
- 2020-05-22 CA CA3141732A patent/CA3141732A1/en active Pending
- 2020-05-22 MX MX2021014306A patent/MX2021014306A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520138A5 (cg-RX-API-DMAC7.html) | ||
| US11639523B2 (en) | Type V CRISPR-Cas systems and use thereof | |
| JP7094323B2 (ja) | 最適化機能CRISPR-Cas系による配列操作のための系、方法および組成物 | |
| Slattery et al. | An expanded plasmid-based genetic toolbox enables Cas9 genome editing and stable maintenance of synthetic pathways in Phaeodactylum tricornutum | |
| AU2015342749B2 (en) | Methods for improving CRISPR/Cas-mediated genome-editing | |
| JP2023508740A5 (cg-RX-API-DMAC7.html) | ||
| WO2022140577A2 (en) | Compositions and methods for epigenetic editing | |
| JP2023541457A5 (cg-RX-API-DMAC7.html) | ||
| US20250304934A1 (en) | Reprogrammable fanzor polynucleotides and uses thereof | |
| Chen et al. | In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA | |
| JP2022538084A5 (cg-RX-API-DMAC7.html) | ||
| Amoasii et al. | In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse | |
| CN109207477A (zh) | 新型crispr酶以及系统 | |
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| Xu et al. | CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity | |
| Yang et al. | CRISPR Cas9 in pancreatic cancer research | |
| CN117136235A (zh) | 用于表观遗传编辑的组合物和方法 | |
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| JP2023528415A5 (cg-RX-API-DMAC7.html) | ||
| JP2024534387A5 (cg-RX-API-DMAC7.html) | ||
| US20260008827A1 (en) | Nuclease-guided non-ltr retrotransposons and uses thereof | |
| CN105624196A (zh) | 一种建立cyp2c11基因敲除大鼠模型的方法 | |
| Mukushkina et al. | In silico prediction of miRNA interactions with candidate atherosclerosis gene mRNAs | |
| JP2022502481A (ja) | 遺伝的に変異された細胞の死滅誘導組成物及び該組成物を用いた遺伝的に変異された細胞の死滅誘導方法 | |
| JP2024528202A5 (cg-RX-API-DMAC7.html) |